IDEAYA Biosciences Inc (NAS:IDYA)
$ 37.71 -0.74 (-1.92%) Market Cap: 2.85 Bil Enterprise Value: 2.16 Bil PE Ratio: 0 PB Ratio: 3.01 GF Score: 37/100

IDEAYA Biosciences Inc at Guggenheim Healthcare Talks Oncology Day Transcript

Feb 09, 2023 / 03:45PM GMT
Release Date Price: $17.41 (+0.64%)
Charles Zhu
Guggenheim Partners - VP, Biotechnology Equity Research

Good morning, everyone. I am Charles Zhu, one of the senior biotech analysts here at Guggenheim Securities. For our next session, we'll be hosting a fireside chat with IDEAYA Biosciences.

Yujiro and Mike, thank you very much for joining us here today. We appreciate your attendance and participation. Perhaps just to get us started off, could you kick off with your company platform and pipeline, please?

Yujiro Hata
IDEAYA Biosciences, Inc. - President & CEO

Great. So thank you so much, Charles, for the kind invitation today. Mike and I will be both -- are participating today at the fireside chat. Yeah, and we'll look forward to the conversation today.

So IDEAYA, we were founded just over seven years ago with a core focus to build the industry leading synthetic lethality-focused precision medicine oncology company. Today, we have three clinical programs. Our most advanced program is darovasertib. Here, we're targeting to have a discussion with the FDA on a potential

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot